Design and evaluation of ocusert for controlled delivery of flurbiprofen sodium

Current Eye Research

Volumn 36, Issue 5, 2011, Pages 436-441

  Kulhari, Hitesh ^a   Pooja, Deep ^a   Narayan, Harihar ^a   Meena, Lokesh ^a   Prajapati, S K ^a  

^a BUNDELKHAND UNIVERSITY   (India)

Author keywords

Drug release; Ethyl cellulose; Eudragit RL100; Flurbiprofen sodium; HPMC; Ocusert

Indexed keywords

EUDRAGIT; FLURBIPROFEN; FLURBIPROFEN SODIUM OCULAR INSERT; HYDROXYPROPYLMETHYLCELLULOSE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED DRUG RELEASE; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG FORMULATION; DRUG SCREENING; DRUG STABILITY; HYDROPHILICITY; HYDROPHOBICITY; IN VITRO STUDY; IN VIVO STUDY; PATIENT COMPLIANCE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; ROOM TEMPERATURE;

ACRYLIC RESINS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELLULOSE; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG EVALUATION; FEMALE; FLURBIPROFEN; HYDROGEN-ION CONCENTRATION; MALE; METHYLCELLULOSE; PATIENT COMPLIANCE; RABBITS; TEMPERATURE;

EID: 79955046282     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713683.2010.542866     Document Type: Article

References (23)

1. Sweetman CS. Martindale: The Complete Drug Reference, 34th ed. London: Pharmaceutical Press, 2005; p. 41.
2. Maurice DM. Kinetics of topically applied drugs. In: Ophthalmic Drug Delivery, Biopharmaceutical, Technological, and Clinical Aspects, Vol. II. Fidia Research Series. Padova, Italy: Liviana Press, 1987; pp. 19-26.
3. Hecht G. Ophthalmic preparations. In: Gennaro AF (Ed.). Remington: The Science and Practice of Pharmacy, Vol. II. Easton, PA: Mack Publishing, 1995; p. 1563.
4. Dey S, Patel J, Anand BS, et al. Molecular evidence and functional expression of P-glycoprotein (MDR1) in human and rabbit cornea and corneal epithelial cell lines. Invest Ophthalmol Vis Sci. 2003;44:2909-2918. (Pubitemid 36759752)
5. Karla PK, Pal D, Quinn T, et al. Molecular evidence and functional expression of a novel drug effux pump (ABCC2) in human corneal epithelium and rabbit cornea and its role in ocular drug effux. Int J Pharm. 2007;336:12-21. (Pubitemid 46551552)
6. Duvvuri S, Majumdar S, Mitra AK. Role of metabolism in ocular drug delivery. Curr Drug Metab. 2004;5:507-515. (Pubitemid 39534495)
7. Mannermaa E, Vellonen KS, Urtti A. Drug transport in cor-neal epithelium and blood-retina barrier: Emerging role of transporters in ocular pharmacokinetics. Adv Drug Deliv Rev. 2006;58:1136-1163.
8. Zhang T, Xiang CD, Gale D, et al. Drug transporter and CYP P450 mRNA expression in human ocular barriers: Implications for ocular drug disposition. Drug Metab Dispos. 2008;36:1300-1307. (Pubitemid 351929314)
9. Dallas S, Miller DS, Bendayan R. Multidrug resistance-associated proteins: Expression and function in the central nervous system. Pharmacol Rev. 2006;58:140-161.
10. Vega E, Gamisans F, García ML, et al. PLGA nano-spheres for the ocular delivery of furbiprofen sodium: Drug release and interactions. J Pharm Sci. 2008;97:5306-5317.
11. Pignatello R, Bucolo C, Spedalieri G, et al. Flurbiprofen sodium-loaded acrylate polymer nanosuspensions for ophthalmic application. Biomaterials. 2002;23:3247-3255. (Pubitemid 34522137)
12. Vega E, Egea MA, Valls O, et al. Flurbiprofen sodium loaded biodegradable nanoparticles for ophthalmic administration. J Pharm Sci. 2006;95:2393-2405. (Pubitemid 44726380)
13. Masuda K, Ikari T, Matsuyama T, Terashima A, Takao G, inventors: Kakenyaku Kako Co. Ltd., Japan, assignee. Antiinfammatory ophthalmic solution and process for preparing the same. US patent 4 474 811. October 2, 1984.
14. Gurtler F, Gunny R. Patent literature review of ophthalmic inserts. Drug Del Ind Pharm. 1995;21:1-18.
15. Chien YW. Ocular drug delivery and delivery systems. In: Novel Drug Delivery Systems. New York: Marcel Dekker Inc., 1996; pp. 269-301.
16. Chiou GCY, Watanabe K. Drug delivery to the eye. Pharm Ther. 1982;17:269-278. (Pubitemid 13236434)
17. Khar RK, Vyas SP. Targeted and Controlled Drug Delivery Novel Carrier Systems, 1st ed. New Delhi:CBS Publishers and Distributors, 2002; p. 384.
18. Saettone MF, Salminen L. Ocular inserts for topical delivery Adv Drug Del Rev. 1995;16:95-106.
19. Castelli F, Messina C, Sarpietro MG, et al. Flurbiprofen sodium release from Eudragit RS and RL aqueous nanosus-pensions: A kinetic study by DSC and dialysis experiments. AAPS PharmSciTech. 2006;3:1-8.
20. Graber, H. Rational antibiotic therapy: New drugs, changing concepts. The Eastern Pharmacist. 1991;7:25-30.
21. Dhanaraju MD, Sivakumar VR, Subhashree R, et al. Bioadhesive ocusert matrix for ophthalmic adminis-tration of ciprofoxacin hydrochloride. Indian Drugs. 2002;39:222-224. (Pubitemid 34873762)
22. Draize JH, Woodward G, Calvery HO. Methods for the study of irritation and toxicity of substance applied topi-cally to the skin and mucous membrane. J Pharmacol Exp Ther. 1944;82:377-390.
23. Dandagi PM, Manvi FV, Patil MB, et al. Development and evaluation of ocular flms of cromolyn sodium. Indian J Pharm Sci. 2004;66:309-312.